Pharma's chain of custody model is migrating into food and consumer goods — and becoming a cross-industry differentiator.
|Videos|May 3, 2022
Pharmaceutical CEO Leadership: Real-World Evidence
Among the topics discussed at Pharm Exec’s recent RWE roundtable are how the pandemic has served to validate the use of RWE/RWD; the most important features of a real-world data set; and key considerations when selecting an RWD partner.
Advertisement
Advertisement
Related to this article
Pharma logistics are overqualified by design — and how agentic AI can now optimize across thousands of lanes in days, not months.
Pharma AI adoption fails not because of the technology — but because organizations deploy tools before they're ready to use them.
CORXEL’s Dr. Bo Liang on why GLP-1 therapies are a broader chronic disease platform — not just obesity drugs — with benefits across cardiovascular, renal, and metabolic disease.
Why GLP-1s achieving bariatric surgery-level efficacy is the field's most surprising advancement of the past decade.
CORXEL’s Dr. Bo Liang on why small molecule oral therapies will be the long-term winners in a GLP-1 market driven by consumer preference.
Advertisement
Advertisement
Trending on PharmExec
1
Viatris Acquires Pacira BioSciences for $1.65 Billion
2
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
3
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
4
Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
5